We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
424 result(s) found, displaying 251 to 260
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: fluticasone furoate, umeclidinium bromide, vilanterol trifenatate.
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INCRUSE ELLIPTA umeclidinium (as bromide) 62.5 microgram powder for inhalation.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ANORO ELLIPTA 62.5/25 umeclidinium (as bromide)/vilanterol (as trifenatate) 62.5 microgram/25 microgram powder for inhalation.